# Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

> **NCT00459108** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00459108
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Halted early for futility.
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00459108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00459108, "Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00459108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*